India Intravenous Anesthetic Market: Restraint
Overdose of Anesthesia causing sudden death
Product recall due to visibility of entities in the sterile preparations a major restraint on the growth of the India intravenous anesthetic market. Moreover, the increase prevalence of overdose of anesthesia leads to the death of the individual cane lead to restrict the growth of intravenous anesthesia. For instance, in September 2022, Central Drugs Standard Control Organization (CDSCO), an India's national regulatory body for cosmetics, pharmaceuticals and medical devices gave a red alert on use of propofol injection, due to sudden death of 5 patients in Chandigarh as the propofol is administered to them prior to any big surgery.
Product recalls from the regulatory body
Certain factors such as potential breakdown in the inhaled preparation of surgical anesthetic is expected to hinder the growth of the India intravenous anesthetic market during the forecast period. To support this, company is planning to support this voluntarily recall by providing another batch manufacturing with no visible entities. A Letter to affected customers informing them of the product issue and potential risks to health is to be provided. For instance, in December, 2021, Getinge sent an Urgent Medical Recall Letter to affected customers informing them of the product issue and potential risks to health. Getinge is recalling the Vaporizer Sevoflurane Maquet filling due to the potential chemical breakdown of Sevoflurane, a general surgical anesthetic, which may result in inhalation and/or skin exposure to harmful chemicals. If this occurs, this may cause serious patient harms including irritation of the respiratory tract, lung edema (swelling caused by excess fluid), and severe hypocalcemia (condition in which the blood has too little calcium).
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients